Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALNY's Cash to Debt is ranked higher than
97% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. ALNY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ALNY' s Cash to Debt Range Over the Past 10 Years
Min: 3.29  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.92
ALNY's Equity to Asset is ranked higher than
88% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALNY: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
ALNY' s Equity to Asset Range Over the Past 10 Years
Min: -0.99  Med: 0.58 Max: 0.92
Current: 0.92
-0.99
0.92
Interest Coverage No Debt
ALNY's Interest Coverage is ranked higher than
96% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ALNY' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: 29.78
M-Score: 9.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -432.92
ALNY's Operating margin (%) is ranked lower than
70% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. ALNY: -432.92 )
Ranked among companies with meaningful Operating margin (%) only.
ALNY' s Operating margin (%) Range Over the Past 10 Years
Min: -800.97  Med: -164.88 Max: -28.95
Current: -432.92
-800.97
-28.95
Net-margin (%) -383.46
ALNY's Net-margin (%) is ranked lower than
70% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. ALNY: -383.46 )
Ranked among companies with meaningful Net-margin (%) only.
ALNY' s Net-margin (%) Range Over the Past 10 Years
Min: -750.77  Med: -143.70 Max: -27.3
Current: -383.46
-750.77
-27.3
ROE (%) -18.19
ALNY's ROE (%) is ranked higher than
60% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. ALNY: -18.19 )
Ranked among companies with meaningful ROE (%) only.
ALNY' s ROE (%) Range Over the Past 10 Years
Min: -84.12  Med: -42.22 Max: -13.08
Current: -18.19
-84.12
-13.08
ROA (%) -16.57
ALNY's ROA (%) is ranked higher than
60% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ALNY: -16.57 )
Ranked among companies with meaningful ROA (%) only.
ALNY' s ROA (%) Range Over the Past 10 Years
Min: -52.19  Med: -21.88 Max: -5.01
Current: -16.57
-52.19
-5.01
ROC (Joel Greenblatt) (%) -1100.77
ALNY's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. ALNY: -1100.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALNY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2120.98  Med: -368.78 Max: -149.42
Current: -1100.77
-2120.98
-149.42
Revenue Growth (3Y)(%) -29.60
ALNY's Revenue Growth (3Y)(%) is ranked lower than
76% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. ALNY: -29.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALNY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 7.90 Max: 108
Current: -29.6
0
108
EBITDA Growth (3Y)(%) 65.40
ALNY's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ALNY: 65.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALNY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.8  Med: -6.10 Max: 65.4
Current: 65.4
-64.8
65.4
EPS Growth (3Y)(%) 52.80
ALNY's EPS Growth (3Y)(%) is ranked higher than
92% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ALNY: 52.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALNY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.8  Med: -3.80 Max: 52.8
Current: 52.8
-66.8
52.8
» ALNY's 10-Y Financials

Financials (Next Earnings Date: 2016-02-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ALNY Guru Trades in Q1 2015

Louis Moore Bacon 5,500 sh (New)
Julian Robertson 161,600 sh (New)
John Griffin 960,000 sh (+123.26%)
Vanguard Health Care Fund 6,094,810 sh (+21.17%)
Pioneer Investments 484,824 sh (+0.33%)
Mairs and Power 2,200 sh (unchged)
Paul Tudor Jones Sold Out
Columbia Wanger 402,500 sh (-15.74%)
» More
Q2 2015

ALNY Guru Trades in Q2 2015

Jim Simons 102,399 sh (New)
Pioneer Investments 630,129 sh (+29.97%)
John Griffin 1,075,000 sh (+11.98%)
Vanguard Health Care Fund 6,094,810 sh (unchged)
Mairs and Power 2,200 sh (unchged)
Columbia Wanger Sold Out
Julian Robertson Sold Out
Louis Moore Bacon Sold Out
» More
Q3 2015

ALNY Guru Trades in Q3 2015

Vanguard Health Care Fund 7,355,914 sh (+20.69%)
Pioneer Investments 632,698 sh (+0.41%)
John Griffin 1,075,000 sh (unchged)
Mairs and Power Sold Out
Jim Simons Sold Out
» More
Q4 2015

ALNY Guru Trades in Q4 2015

Vanguard Health Care Fund 7,583,610 sh (+3.10%)
» More
» Details

Insider Trades

Latest Guru Trades with ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 23.64
ALNY's Forward P/E is ranked lower than
70% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.89 vs. ALNY: 23.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.27
ALNY's P/B is ranked lower than
75% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. ALNY: 4.27 )
Ranked among companies with meaningful P/B only.
ALNY' s P/B Range Over the Past 10 Years
Min: 2.07  Med: 4.86 Max: 21.38
Current: 4.27
2.07
21.38
P/S 93.45
ALNY's P/S is ranked lower than
93% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. ALNY: 93.45 )
Ranked among companies with meaningful P/S only.
ALNY' s P/S Range Over the Past 10 Years
Min: 3.09  Med: 20.80 Max: 189.72
Current: 93.45
3.09
189.72
Current Ratio 18.24
ALNY's Current Ratio is ranked higher than
88% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. ALNY: 18.24 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.59 Max: 18.24
Current: 18.24
1.88
18.24
Quick Ratio 18.24
ALNY's Quick Ratio is ranked higher than
88% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. ALNY: 18.24 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.59 Max: 18.24
Current: 18.24
1.88
18.24
Days Sales Outstanding 51.55
ALNY's Days Sales Outstanding is ranked higher than
61% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. ALNY: 51.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.57  Med: 34.48 Max: 288.31
Current: 51.55
0.57
288.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.16
ALNY's Price/Net Cash is ranked higher than
50% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ALNY: 6.16 )
Ranked among companies with meaningful Price/Net Cash only.
ALNY' s Price/Net Cash Range Over the Past 10 Years
Min: 3.7  Med: 9.40 Max: 92.77
Current: 6.16
3.7
92.77
Price/Net Current Asset Value 5.99
ALNY's Price/Net Current Asset Value is ranked lower than
53% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. ALNY: 5.99 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALNY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.54  Med: 9.18 Max: 82.06
Current: 5.99
3.54
82.06
Price/Tangible Book 4.20
ALNY's Price/Tangible Book is ranked lower than
51% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ALNY: 4.20 )
Ranked among companies with meaningful Price/Tangible Book only.
ALNY' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.2  Med: 4.90 Max: 15.17
Current: 4.2
2.2
15.17
Price/Median PS Value 4.44
ALNY's Price/Median PS Value is ranked lower than
93% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALNY: 4.44 )
Ranked among companies with meaningful Price/Median PS Value only.
ALNY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 1.01 Max: 7.41
Current: 4.44
0.16
7.41
Earnings Yield (Greenblatt) (%) -5.51
ALNY's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ALNY: -5.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALNY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -6  Med: 465.90 Max: 1781.6
Current: -5.51
-6
1781.6

More Statistics

Revenue(Mil) $58
EPS $ -2.66
Beta2.25
Short Percentage of Float9.61%
52-Week Range $61.09 - 140.00
Shares Outstanding(Mil)84.74

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 54 129 63 199
EPS($) -2.81 -2.60 -2.72 -1.53
EPS without NRI($) -2.81 -2.60 -2.72 -1.53

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DUL.Germany,
Alnylam Pharmaceuticals Inc was originally incorporated in Delaware under the name Alnylam Holding Co. on May 8, 2003. It is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The Company's research and development is focused primarily on use of its proprietary N-acetylgalactosamine, or GalNAc-conjugate for delivery of small interfering RNAs, or "siRNAs" - the molecules that mediate RNAi - toward liver-expressed genes involved in the cause or pathway of human diseases. It is also focused on clinical indications where there are high unmet medical needs, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval and commercialization. The Company operates in a single reporting segment, the discovery, development and commercialization of RNAi therapeutics. Its competitors include Takeda, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando Pharmaceuticals, Inc., or Calando, Quark Pharmaceuticals, Inc., or Quark, Silence Therapeutics plc, Tekmira, Sylentis, S.A.U., or Sylentis, Dicerna Pharmaceuticals, Inc. and Arcturus Therapeutics, among others. The research, testing, manufacture and marketing of drug products and their delivery systems are extensively regulated in the United States and the rest of the world.
» More Articles for ALNY

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam Pharmaceutical Nov 17 2015 
Julian Robertson Boosts His Stakes in JD.com, Netflix Oct 06 2015 
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 
Gurus Purchase Tekmira Pharmaceuticals in Q1 Jun 19 2015 
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CEO Buys Highlight: VITC, CTFO, RPM, EFC, ALNY Oct 17 2011 

More From Other Websites
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2015 Financial Results Feb 04 2016
Alnylam to Webcast Presentations at Upcoming February Investor Conferences Feb 01 2016
Alnylam to Webcast Presentations at Upcoming February Investor Conferences Feb 01 2016
Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi... Feb 01 2016
Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi... Feb 01 2016
Coverage initiated on Alnylam Pharma by Credit Suisse Jan 20 2016
Alnylam Provides Update on RNAi Therapeutics Pipeline Jan 13 2016
Alnylam Pharmaceuticals Dips Lower After Company Announces 2016 Pipeline Goals Towards 'Alnylam... Jan 11 2016
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 11 2016
Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline Jan 11 2016
Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline Jan 11 2016
BioMarin Announces Addition of David Pyott, Former Allergan Chairman and CEO, to Company’s Board... Jan 04 2016
Alnylam to Webcast Presentation at 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
Alnylam to Webcast Presentation at 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
Alnylam to Webcast Presentation at Goldman Sachs "Healthcare CEOs Unscripted: A View from the Top"... Dec 29 2015
Alnylam to Webcast Presentation at Goldman Sachs “Healthcare CEOs Unscripted: A View from the... Dec 29 2015
Sell These 6 Biotech Stocks Now Before It's Too Late Dec 26 2015
Alnylam Initiates Clinical Trial, SPDR S&P Biotech Mid-Caps Plunge Anyway Dec 25 2015
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change... Dec 22 2015
Alnylam Submits Clinical Trial Application for ALN-GO1 in UK Dec 22 2015
Alnylam Files Clinical Trial Application (CTA) for ALN-GO1, an Investigational RNAi Therapeutic for... Dec 21 2015
Alnylam Files Clinical Trial Application (CTA) for ALN-GO1, an Investigational RNAi Therapeutic for... Dec 21 2015
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 18 2015
Alnylam Initiates Final Part of Phase I/II Study on ALN-CC5 Dec 18 2015
Alnylam Announces Updates to Company's Board of Directors Supportive of Transition Towards... Dec 18 2015
Alnylam Announces Updates to Company’s Board of Directors Supportive of Transition Towards... Dec 18 2015
Alnylam Initiates Dosing in PNH Patients in Phase 1/2 Clinical Trial for ALN-CC5 Dec 17 2015
Alnylam Initiates Dosing in PNH Patients in Phase 1/2 Clinical Trial for ALN-CC5 Dec 17 2015
Alnylam Pharmaceuticals to Present Path to "Alnylam 2020" at R&D Day Dec 10 2015
Alnylam Reports that ALN-CC5 Achieves Up to 99 Percent Knockdown of Serum C5 and Up to 98 Percent... Dec 06 2015
Alnylam to Webcast R&D Day Dec 02 2015
Alnylam to Webcast Presentations at Upcoming December Investor Conferences Nov 23 2015
Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from... Nov 11 2015
Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from... Nov 11 2015
Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results and Highlights from Recent... Nov 09 2015
Alnylam reports 3Q loss Nov 09 2015
Alnylam to Present New Clinical Results with Investigational RNAi Therapeutics at 57th Annual... Nov 05 2015
Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension (OLE) Studies for... Nov 03 2015
Alnylam to Webcast Presentations at Upcoming November Conferences Nov 02 2015
Alnylam to Webcast Conference Call Discussing Third Quarter 2015 Financial Results Nov 02 2015
Alnylam to Report New Clinical Results with Investigational RNAi Therapeutics for the Treatment of... Oct 29 2015
Medicines shares surge on upbeat cholesterol drug study Aug 31 2015
ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for... Aug 30 2015
Alnylam reports 2Q loss Aug 06 2015
Alnylam reports 1Q loss May 07 2015
Alnylam reports 4Q loss Feb 12 2015
Alnylam beats Street 3Q forecasts Nov 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK